BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Q4 2024 Earnings Call Mar 10, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants. P ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you. Good ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

BioNTech (NASDAQ:BNTX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per ...

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Three ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best immunology stocks to buy now. Immunology is a rapidly advancing field with significant ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...